Clearbridge Investments
Clearbridge Small Cap Strategy
Small-cap
Dec 2024 → Sep 2025
Our archive holds 2 letters from this strategy, behind 2 investment theses and positions in 26 companies. Every quote below is copied verbatim from the letter it came from.
2 letters in 2 years · follow all of Clearbridge Investments for every strategy.
What it bought and sold
We exited positions in GoodRx and Ultragenyx Pharmaceutical in the health care sector, Oxford Industries in the consumer discretionary sector, Anterix in the communication services sector, Wabash National in the industrials sector, ASGN in the IT sector and LXP Industrial Trust in the real estate sector.
We exited positions in GoodRx and Ultragenyx Pharmaceutical in the health care sector, Oxford Industries in the consumer discretionary sector, Anterix in the communication services sector, Wabash National in the industrials sector, ASGN in the IT sector and LXP Industrial Trust in the real estate sector.
In addition to the transactions listed above, we initiated new positions in CG Oncology, Celcuity and Bicara Therapeutics in the health care sector, Freshpet in the consumer staples sector and Piedmont Realty Trust in the real estate sector.
In addition to the transactions listed above, we initiated new positions in CG Oncology, Celcuity and Bicara Therapeutics in the health care sector, Freshpet in the consumer staples sector and Piedmont Realty Trust in the real estate sector.
We exited positions in GoodRx and Ultragenyx Pharmaceutical in the health care sector, Oxford Industries in the consumer discretionary sector, Anterix in the communication services sector, Wabash National in the industrials sector, ASGN in the IT sector and LXP Industrial Trust in the real estate sector.
We exited positions in GoodRx and Ultragenyx Pharmaceutical in the health care sector, Oxford Industries in the consumer discretionary sector, Anterix in the communication services sector, Wabash National in the industrials sector, ASGN in the IT sector and LXP Industrial Trust in the real estate sector.
In addition to the transactions listed above, we initiated new positions in CG Oncology, Celcuity and Bicara Therapeutics in the health care sector, Freshpet in the consumer staples sector and Piedmont Realty Trust in the real estate sector.
In addition to the transactions listed above, we initiated new positions in CG Oncology, Celcuity and Bicara Therapeutics in the health care sector, Freshpet in the consumer staples sector and Piedmont Realty Trust in the real estate sector.
We exited positions in GoodRx and Ultragenyx Pharmaceutical in the health care sector, Oxford Industries in the consumer discretionary sector, Anterix in the communication services sector, Wabash National in the industrials sector, ASGN in the IT sector and LXP Industrial Trust in the real estate sector.
We initiated a position as the company appeared to be nearing the bottom of its estimate revision cycle, with embedded expectations that seemed overly pessimistic relative to its long-term growth prospects.
We exited positions in GoodRx and Ultragenyx Pharmaceutical in the health care sector, Oxford Industries in the consumer discretionary sector, Anterix in the communication services sector, Wabash National in the industrials sector, ASGN in the IT sector and LXP Industrial Trust in the real estate sector.
We exited positions in GoodRx and Ultragenyx Pharmaceutical in the health care sector, Oxford Industries in the consumer discretionary sector, Anterix in the communication services sector, Wabash National in the industrials sector, ASGN in the IT sector and LXP Industrial Trust in the real estate sector.
We exited our position in Vivid Seats, an online ticket marketplace that connects fans with live event tickets.
In addition to the transactions listed above, we initiated new positions in CG Oncology, Celcuity and Bicara Therapeutics in the health care sector, Freshpet in the consumer staples sector and Piedmont Realty Trust in the real estate sector.
We also established a new position in Avidity Biosciences, a development-stage biotechnology company with a proprietary platform for delivering RNA-based therapeutics to muscle tissue.
Also held
Its investment theses
- Quaker HoughtonSep 2025Quaker Houghton is well-positioned for above-industry average growth due to its resilient business model and optimistic long-term prospects despite current pessimistic expectations.
- First Watch RestaurantDec 2024First Watch Restaurant is an attractive growth opportunity in casual dining, focusing on breakfast and lunch to maintain low labor costs and high margins.